What Symbiotec Pharmalab does

Symbiotec Pharmalab is a Madhya Pradesh-based Active Pharmaceutical Ingredient (API) manufacturer that develops and markets corticosteroid and steroidal-hormone APIs to pharmaceutical formulation companies globally. Founded in 2002 and headquartered in Indore, the company operates two manufacturing facilities and reports 36.2% global volume share in corticosteroid APIs and 44.2% in steroidal-hormone APIs. Its product portfolio has historically centered on bulk steroid APIs but is expanding into high-potency APIs (HPAPI), CDMO services, and finished formulations under India's Production Linked Incentive (PLI) scheme, where it has completed over 30 projects.

The company sells APIs directly to formulation manufacturers via B2B contracts with quote-based pricing, generating FY 2024-25 revenue of Rs 751.6 crore and profit of Rs 96.8 crore. Ownership is anchored by institutional investors including Rosewood Investments (Motilal Oswal-backed) and India Business Excellence Fund III (InvAscent-managed), with prior capital from Actis. Symbiotec filed its DRHP with SEBI on December 19, 2025 for a Rs 2,180 crore IPO (Rs 150 crore fresh issue plus Rs 2,030 crore offer-for-sale), and received SEBI approval in March 2026, with listing planned on BSE and NSE. The fresh issue proceeds will primarily prepay Rs 112.5 crore of debt, with the balance for general corporate purposes.

The business model is concentrated in a single therapeutic-adjacent vertical (steroid and hormone chemistry) with a horizontally diversified buyer base of formulation companies across regulated and semi-regulated markets. Go-to-market is direct enterprise sales supplemented by industry events and PLI/regulatory credentials as credibility signals. The company claims global leadership in its niches but operates with a lean headcount of 51-100, reflecting process-manufacturing economics rather than technology-platform scaling.

Name

Symbiotec Pharmalab

Legal name

Symbiotec Pharmalab Limited

Website

https://symbiotec.in

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

51–100 employees

Short description

Symbiotec Pharmalab is an India-based API manufacturer specializing in corticosteroid and steroidal-hormone active pharmaceutical ingredients, supplying pharmaceutical formulation companies globally from two Madhya Pradesh facilities and claiming 36-44% global volume share.

Ownership category

akta.pro rank

Product category

Active Pharmaceutical Ingredients (API) Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Chemicals & Allied Products (2800)

akta.pro primary industry

Small-Molecule API Commercial Manufacturing (HLAGAHAB)

akta.pro secondary industries

High-Potency API (HPAPI) Development & Manufacturing (HLAGAHAC), Small-Molecule API Process Development & Route Scouting (HLAGAHAA), Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

Keywords

• Corticosteroid API manufacturing
• Steroidal hormone APIs
• Active pharmaceutical ingredients
• High-potency API manufacturing
• Pharmaceutical contract manufacturing

Headquarters

HQ city

Indore

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Active Pharmaceutical Ingredient (API) Sales: Symbiotec Pharmalab manufactures and sells APIs (Active Pharmaceutical Ingredients) to pharmaceutical companies globally. The company operates API manufacturing facilities and supplies corticosteroid and steroidal-hormone APIs to formulation manufacturers. Revenue is generated through product sales of APIs to pharmaceutical clients.

Distribution channels1 record

Marketing channels2 records

Core offering

Symbiotec Pharmalab manufactures and sells Active Pharmaceutical Ingredients (APIs), with a specialized focus on corticosteroid and steroidal-hormone APIs supplied to pharmaceutical formulation manufacturers worldwide. The company operates two API manufacturing facilities in Madhya Pradesh, India, and has expanded into high-potency APIs (HPAPIs) under the Government of India's Production Linked Incentive (PLI) scheme. It claims global leadership positions with 36.2% volume market share in corticosteroid APIs and 44.2% in steroidal-hormone APIs.

Product overview

Symbiotec Pharmalab is a Madhya Pradesh-based pharmaceutical and biotechnology company that manufactures Active Pharmaceutical Ingredients (APIs). The company operates two API manufacturing facilities and has completed over 30 projects under the government's Production Linked Incentive (PLI) scheme. The product portfolio centers on two core offerings: Corticosteroid APIs and Steroidal-Hormone APIs, where the company claims global leadership positions with 36.2% and 44.2% volume market shares respectively. The company is preparing for an IPO to raise Rs 2,180 crore, with plans to list on both BSE and NSE.

Differentiator

Problem solved

Functional benefit

Products and services

• Corticosteroid Active Pharmaceutical Ingredients Large-scale manufactured corticosteroid APIs supplied to global pharmaceutical formulation manufacturers for use as raw material inputs in finished dosage forms. Symbiotec holds a 36.2% global volume market share in this segment and claims global leadership.
• Steroidal-Hormone Active Pharmaceutical Ingredients Steroidal-hormone APIs for pharmaceutical applications, supplied to formulation manufacturers for use in finished dosage forms. Symbiotec holds a 44.2% global volume market share in this segment and claims global leadership.
• High-Potency API (HPAPI) Manufacturing Specialized manufacturing of complex, high-potency APIs for pharmaceutical companies, completed via projects under the Government of India's PLI scheme aimed at reducing domestic API import dependency.

Quantifiable outcome

• 36.2% volume market share in corticosteroid APIs globally
• +2 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Government of India (PLI Scheme)significantStrategic or Co-development Partner · 2 March 2026Symbiotec Pharmalab has completed projects under the Production Linked Incentive (PLI) scheme promoted by the Government of India. The company is among several pharma firms including Aurobindo Pharma, Hetero Group, and Macleods Pharma that have completed over 30 PLI projects, supporting domestic API manufacturing and reducing import dependency.

Scale indicators7 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Divi's Laboratories: India-based leading manufacturer of active pharmaceutical ingredients (APIs) and intermediates, with strong presence in steroid and complex API categories — a directly comparable API manufacturing platform with similar export-driven B2B model.
• Cambrex Corporation: Global contract API manufacturer with explicit High-Potency API (HPAPI) capabilities serving branded and generic pharma customers. Comparable to Symbiotec on small-molecule API manufacturing at commercial scale and HPAPI specialization.
• Hovione: Independent global API manufacturer specializing in complex, high-potency and particle-engineered APIs. Highly comparable to Symbiotec on the HPAPI/specialty API manufacturing axis and B2B pharma customer base.

Broad incumbents

• Aurobindo Pharma: Large Indian pharmaceutical company with vertically integrated API manufacturing and a fellow PLI scheme participant. Overlaps with Symbiotec on API manufacturing for global generic formulation customers, but operates across a much broader therapeutic portfolio.
• Cipla: Major Indian pharmaceutical manufacturer with significant in-house API capabilities serving global markets. Comparable to Symbiotec in being an Indian API/formulation exporter, though at far greater scale and breadth of therapeutic categories.
• Dr. Reddy's Laboratories: Large Indian pharmaceutical company with vertically integrated API and formulation operations. Comparable to Symbiotec as a domestic API supplier serving global generic markets, though with broader finished-dose exposure.
• Lupin: Indian pharmaceutical major with API manufacturing capabilities supplying global markets. Overlaps with Symbiotec on India-based small-molecule API production for generic formulations, but operates at much larger scale across multiple therapeutic areas.
• Curia Global (formerly Albany Molecular Research): Global contract development and manufacturing organization (CDMO) with API manufacturing services. Comparable to Symbiotec's emerging CDMO/HPAPI ambitions and B2B pharma services model.

Emerging players

• Sequent Scientific: Indian API manufacturer focused on steroids and hormones for animal and human health. Directly comparable to Symbiotec in steroidal-hormone API manufacturing, making it one of the closest niche competitors in the corticosteroid/steroid space.

Regional players

• Shandong Xinhua Pharmaceutical: Chinese API manufacturer with significant global share in steroid and corticosteroid APIs. Comparable to Symbiotec as a primary cost-competitive steroid API competitor, though based in the dominant Chinese supply region.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

• Xx.com/Symbiotec_SPL
• Facebookfacebook.com/Symbiotec
• LinkedInlinkedin.com/company/symbiotec-pharmalab-pvt-ltd-

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Symbiotec Pharmalab